Cover Image

The AMPK-mTOR Pathway Is Inhibited by Chaihu Shugan Powder, Which Relieves Nonalcoholic Steatohepatitis by Suppressing Autophagic Ferroptosis

Nonalcoholic steatohepatitis (NASH) is the advanced stage of nonalcoholic fatty liver disease (NAFLD), which is distinguished by the accumulation of fat in the liver, damage to liver cells, and inflammation. Chaihu Shugan powder (CSP), a renowned traditional Chinese medicine (TCM) blend extensively...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zheng Liang (Author), Dajin Pi (Author), Jianwei Zhen (Author), Haizhen Yan (Author), Chuiyang Zheng (Author), July Liang Chen (Author), Wen Fan (Author), Qingliang Song (Author), Jinyue Pan (Author), Dongdong Liu (Author), Maoxing Pan (Author), Qinhe Yang (Author), Yupei Zhang (Author)
Format:	Book
Published:	Hindawi Limited, 2024-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Tanshinone IIA Inhibits the Endoplasmic Reticulum Stress-Induced Unfolded Protein Response by Activating the PPARα/FGF21 Axis to Ameliorate Nonalcoholic Steatohepatitis
by: Dajin Pi, et al.
Published: (2024)

Chaihu-Shugan-San ameliorates tumor growth in prostate cancer promoted by depression via modulating sphingolipid and glycerinphospholipid metabolism
by: Wei Li, et al.
Published: (2022)

Chaihu Shugan prevents cholesterol gallstone formation by ameliorating the microbiota dysbiosis and metabolic disturbance in mice
by: Wei Wang, et al.
Published: (2024)

SIRT1/FOXO1 Axis-Mediated Hippocampal Angiogenesis is Involved in the Antidepressant Effect of Chaihu Shugan San
by: Zhang S, et al.
Published: (2022)

Potential antidepressant effects of Traditional Chinese botanical drug formula Chaihu-Shugan-San and its active ingredients
by: Ziyi Guo, et al.
Published: (2024)

Chaihu Shugan San promotes gastric motility in rats with functional dyspepsia by regulating Drp-1-mediated ICC mitophagy
by: Li Li, et al.
Published: (2023)

Chaihu Shugan San ameliorated cognitive deficits through regulating gut microbiota in senescence-accelerated mouse prone 8
by: Zhiyue Li, et al.
Published: (2023)

Network Pharmacology and Experimental Evidence: PI3K/AKT Signaling Pathway is Involved in the Antidepressive Roles of Chaihu Shugan San
by: Zhang S, et al.
Published: (2021)

Chaihu Shugan powder alleviates liver inflammation and hepatic steatosis in NAFLD mice: A network pharmacology study and in vivo experimental validation
by: Sisi Lei, et al.
Published: (2022)

Hepatic COX1 loss leads to impaired autophagic flux and exacerbates nonalcoholic steatohepatitis
by: Qian Yu, et al.
Published: (2023)

Proteomics Study Reveals the Anti-Depressive Mechanisms and the Compatibility Advantage of Chaihu-Shugan-San in a Rat Model of Chronic Unpredictable Mild Stress
by: Xiaofei Zhu, et al.
Published: (2022)

Chaihu Shugan powder restores fatty acid synthesis to alleviate insulin resistance in metabolic syndrome by regulating the LXRα/SREBP-1 signaling pathway
by: Sisi Lei, et al.
Published: (2024)

Chaihu-Shugan-San (Shihosogansan) alleviates restraint stress-generated anxiety and depression in mice by regulating NF-κB-mediated BDNF expression through the modulation of gut microbiota
by: Sang-Kap Han, et al.
Published: (2021)

Chaihu-shugan-san alleviates depression-like behavior in mice exposed to chronic unpredictable stress by altering the gut microbiota and levels of the bile acids hyocholic acid and 7-ketoDCA
by: Chong Ma, et al.
Published: (2022)

The Modulation of Chaihu Shugan Formula on Microbiota Composition in the Simulator of the Human Intestinal Microbial Ecosystem Technology Platform and its Influence on Gut Barrier and Intestinal Immunity in Caco-2/THP1-Blue™ Cell Co-Culture Model
by: Ling Liu, et al.
Published: (2022)

Commentary: The Modulation of Chaihu Shugan Formula on Microbiota Composition in the Simulator of the Human Intestinal Microbial Ecosystem Technology Platform and Its Influence on Gut Barrier and Intestinal Immunity in Caco-2/THP1-Blue™ Cell Co-Culture Model
by: Yang Yu, et al.
Published: (2022)

Oligonucleotide therapies for nonalcoholic steatohepatitis
by: Sixu Li, et al.
Published: (2024)

Toosendanin Induces Hepatocyte Damage by Inhibiting Autophagic Flux via TFEB-Mediated Lysosomal Dysfunction
by: Li Luo, et al.
Published: (2022)

Schisandra lignans ameliorate nonalcoholic steatohepatitis by regulating aberrant metabolism of phosphatidylethanolamines
by: Lijuan Xue, et al.
Published: (2023)

Ductular reaction in alcoholic steatohepatitis, nonalcoholic steatohepatitis and hepatitis C virus infection (immunohistochemical study)
by: O. M. Gavrilyuk
Published: (2014)

Semaglutide in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
by: Magdalena Mazurek, et al.
Published: (2023)

Serum Adipokine and Ghrelin Levels in Nonalcoholic Steatohepatitis
by: Mehmet Yalniz, et al.
Published: (2006)

Microbiota-derived tryptophan metabolism and AMPK/mTOR pathway mediate antidepressant-like effect of Shugan Hewei Decoction
by: Yingying Yue, et al.
Published: (2024)

Efficacy of Shugan Hewei Therapy for Chronic Atrophic Gastritis: A Systematic Review and Meta-Analysis
by: Jing-Bin Niu, et al.
Published: (2022)

The autophagic regulation of rosiglitazone-promoted adipocyte browning
by: Yue Li, et al.
Published: (2024)

Bardet-Biedl syndrome with nonalcoholic steatohepatitis, hypertension, and hypothyroidism
by: Yatendra Singh, et al.
Published: (2016)

Correction: Medaka as a model for human nonalcoholic steatohepatitis
by: Toshihiko Matsumoto, et al.
Published: (2023)

Shugan Jieyu Capsule in Post-Stroke Depression Treatment: From Molecules to Systems
by: Meng Zhang, et al.
Published: (2022)

Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options
by: Milic S, et al.
Published: (2015)

Psoralea corylifolia L. Attenuates Nonalcoholic Steatohepatitis in Juvenile Mouse
by: Lishan Zhou, et al.
Published: (2017)

Triglyceride peroxidation progression in lipid droplets of hepatocytes in nonalcoholic steatohepatitis
by: Kota Saito, et al.
Published: (2024)

Ferroptosis plays a novel role in nonalcoholic steatohepatitis pathogenesis
by: Fei Xiong, et al.
Published: (2022)

Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice
by: Panshuang Qiao, et al.
Published: (2022)

Adipokines in Nonalcoholic Steatohepatitis: From Pathogenesis to Implications in Diagnosis and Therapy
by: Emmanuel A. Tsochatzis, et al.
Published: (2009)

Taurine and tea polyphenols combination ameliorate nonalcoholic steatohepatitis in rats
by: Wenhua Zhu, et al.
Published: (2017)

Jiang Zhi Granule protects immunological barrier of intestinal mucosa in rats with non-alcoholic steatohepatitis
by: Xiao Yu, et al.
Published: (2021)

Scoparone Improves Nonalcoholic Steatohepatitis Through Alleviating JNK/Sab Signaling Pathway-Mediated Mitochondrial Dysfunction
by: Yuwei Jiang, et al.
Published: (2022)

Evodiamine decreased the systemic exposure of pravastatin in non-alcoholic steatohepatitis rats due to the up-regulation of hepatic OATPs
by: Ruifeng Liang, et al.
Published: (2022)

Unveiling the Mechanism of the ChaiShao Shugan Formula Against Triple-Negative Breast Cancer
by: Fan T, et al.
Published: (2024)

Metformin Alleviates Steatohepatitis in Diet-Induced Obese Mice in a SIRT1-Dependent Way
by: Wan-rong Guo, et al.
Published: (2021)